Share this with FacebookShare this with TwitterShare this with LinkedInEmail this pagePrint this page
FOX4: Clinical Trial for New Breast Cancer Drug Shows Positive Results
HER2-positive breast cancer impacts 20-30 percent of all breast cancer patients. This form of breast cancer tends to be more aggressive and impact younger women.
A recent clinical trial has shown promising results and may offer another treatment option for these patients. Phase 3 of the SOPHIA study looked at the impact of a new drug called Margetuximab.
FOX4 talked to Dr. Tim Pluard, the medical director of Saint Luke's Cancer Institute, about what this means for these breast cancer patients.
Watch the full video below.